The Effect of Variants in Five Genes in the Glucagon Pathway on Type 2 Diabetes Risk and Diabetes-Related Traits
MetadataShow full item record
Other TitlesThe Effect of Variants in 5 Genes in the Glucagon Pathway on Type 2 Diabetes Risk and Diabetes-Related Traits
AbstractThe CDC estimates that 29.1 million Americans have type 2 diabetes, which is currently the seventh leading cause of death in the US. It has been proposed that disordered glucagon regulation is a major contributor to the diabetic phenotype. We hypothesized that variants in five genes in the glucagon pathway are associated with response of diabetes-related glucose, insulin, and body composition traits to three antidiabetic interventions in the DPP and that rare coding variants would be enriched compared to other populations and associated with type 2 diabetes and diabetes-related traits in the Old Order Amish (OOA). We have discovered an association between the GCG variant, rs5649, that is predicted to modify the consensus splice site, with increased baseline-adjusted fasting glucose at one year in the metformin and placebo groups but not in the other two treatment groups, suggesting that it may change the structure of glucagon and decrease the ability of metformin to reduce glucagon signaling. We have performed the only known study of a PCSK2 coding variant common in any population. We found this variant, R430W, and the GCGR variant D458H to be twice as common among OOA individuals with diabetes as those with normal or impaired glucose tolerance, although this difference is not statistically significant. In addition, we examined the relationship between the GCGR coding variant G40S and type 2 diabetes risk that has been previously reported and did not see an association despite being better powered than previous studies because of the increased allele frequency of 14% in the OOA population. Finally, we described the only reported GCGR G40S homozygotes, none of whom have type 2 diabetes. In sum, we have provided data on the effects of variants in five genes in the glucagon pathway that can be used in future work to understand the contribution of the glucagon pathway to type 2 diabetes and to inform the development of antidiabetic treatments targeting this pathway.
DescriptionUniversity of Maryland, Baltimore. Epidemiology and Preventive Medicine. Ph.D. 2016
Keyworddiabetes prevention program
Old Order Amish
prohormone convertase 2
Diabetes Mellitus, Type 2
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/5464
Showing items related by title, author, creator and subject.
Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategiesWeir, M.R. (John Wiley and Sons Inc., 2019)
Use of Insulin and Risk of Cancer among Patients with Diabetes Mellitus: A Nonconcurrent Prospective StudyLu, Zhiqiang; Weiss-Smith, Sheila (2011-01)Objectives: There have been a number of studies showing an association between diabetes and cancer risk and a growing concern that this risk maybe linked to insulin therapy. This study aimed to (1) to assess the effect of insulin exposure on the risk of developing solid cancer among patients with diabetes mellitus; and (2) to explore the role of HbA1c value in modifying the risk. Methods: The study used the General Practice Research Database (GPRD), a large UK-based research database of patient electronic health records from general practitioners, to explore the use of insulin on the risk of cancer. Cox's Proportional hazards models were used to estimate the hazard ratio of solid tumors, all sites and selected individual sites, by types of antidiabetic therapy. The potential modifying role of diabetes control as measured by hemoglobin A1c (HbA1c) was also explored. Results: The study cohort contained a total of 230,330 patients with claims for antidiabetic therapy. The study found that use of insulin alone or in combination with other oral agents was associated with an increased risk of cancer. Insulin use was strongly associated with pancreatic cancer risk (HR=1.875, 95% CI 1.261, 2.787 for insulin alone and HR=2.330, 95% CI 2.007, 2.705 for insulin with oral agents). Moreover, HbA1c appears to be a risk factor for pancreatic cancer (HR=1.385, 95% CI 1.324, 1.450). The risk of pancreatic cancer was similarly increased for premixed and intermediate-acting insulin when compared with short-acting insulins. Role of HbA1c value in modifying the risk of cancer among patients with diabetes varies across different cancer types. Conclusion: Use of insulin, alone or in combination with oral agents, may pose a strong risk for pancreatic cancer and overall cancer. Use of insulin alone was also associated with an increased risk of colorectal cancer. These data suggest that there may be more than one mechanism by which insulin therapy impacts the risk of cancer among diabetics. Glucose control appears to impact the risk of pancreatic cancer, though it may be an independent factor for some common tumors. Caution should be used when prescribing insulin to patients for diabetes management.
Community-Driven Priorities in Smartphone Application Development: Leveraging Social Networks to Self-Manage Type 2 Diabetes in a Low-Income African American NeighborhoodSurkan, P.J.; Lagerros, Y.T.; Quinn, C.C. (MDPI AG, 2019)Social networks have the potential to enhance Type 2 Diabetes Mellitus (T2DM) self-management. We used qualitative methods to study if and how mobile application (app) functions that mobilize social resources to improve T2DM management would be desired in a low-income African American community. Data were collected through community discussions and in-depth interviews with 78 participants in 2016–2018. Participants included individuals with self-reported pre-diabetes, T2DM, close family members or friends of a T2DM patient, and healthcare providers. Open-ended questions solicited information about challenges with T2DM management and gathered ideas on features of a mobile app that could address them. Data were transcribed and thematically coded by two coders using Atlas-ti. Regarding types of app functions, main themes included: (1) the importance of having support in diabetes self-care; (2) using informal networks to help to each other; and (3) monitoring one another through an app. Suggested app features included reminders for and transportation to medical visits, sharing information and exercise companionship, and providing opportunities for monitoring by friends/family members, especially in case of emergencies. Participants viewed an app as a potential vehicle for reinforcing accomplishments in T2DM self-management. Future research should implement and test an app with these features in this or similar communities. Copyright 2019 by the authors. Licensee MDPI, Basel, Switzerland.